Quest Diagnostics Inc.
Quest Diagnostics (DGX) is a leading US clinical laboratory services company that provides diagnostic testing, information and services to healthcare providers, hospitals, employers and insurers. Its business is driven by volume of tests, reimbursement rates and specialised, higher-margin diagnostics such as molecular and genomics testing. The company benefits from scale, extensive logistics and long-term contracts but faces competition from other national labs, hospital systems and growing point-of-care testing. Key investor considerations include demand trends for routine and specialised tests, reimbursement and regulatory pressure, and capital investment in automation and new technologies. Quest has historically returned cash via dividends and buybacks, though investors should weigh yield against growth prospects and margin sensitivity. Market cap is about $20.54bn. This summary is for general educational purposes only and is not personalised investment advice; values can fall as well as rise and you should consider your circumstances or speak with a financial adviser.
Why It's Moving
Quest Diagnostics Shares Weigh Near-Term on Q4 EPS Revision Amid Strong Full-Year Outlook
Shares of Quest Diagnostics (DGX) experienced mild pressure following a short-term EPS downgrade for Q4 2025 by Leerink, despite analysts raising their full-year and longer-term earnings estimates. This mixed sentiment coincides with insider selling and highlights investor caution ahead of upcoming quarterly results.
- Leerink lowered Q4 2025 EPS estimate from $2.45 to $2.39, signaling potential near-term earnings softness despite confidence in full-year performance.
- Director Gary M. Pfeiffer sold approximately 1,482 shares (~$270k), a move interpreted as a modest negative indicator by market participants.
- Long-term growth prospects remain solid with expectations for revenue and adjusted EPS growth driven by demand for advanced diagnostic testing and personalized medicine solutions.
Quest Diagnostics Shares Weigh Near-Term on Q4 EPS Revision Amid Strong Full-Year Outlook
Shares of Quest Diagnostics (DGX) experienced mild pressure following a short-term EPS downgrade for Q4 2025 by Leerink, despite analysts raising their full-year and longer-term earnings estimates. This mixed sentiment coincides with insider selling and highlights investor caution ahead of upcoming quarterly results.
- Leerink lowered Q4 2025 EPS estimate from $2.45 to $2.39, signaling potential near-term earnings softness despite confidence in full-year performance.
- Director Gary M. Pfeiffer sold approximately 1,482 shares (~$270k), a move interpreted as a modest negative indicator by market participants.
- Long-term growth prospects remain solid with expectations for revenue and adjusted EPS growth driven by demand for advanced diagnostic testing and personalized medicine solutions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Quest Diagnostics' stock with a target price of $160.86, suggesting growth potential.
Financial Health
Quest Diagnostics is showing strong revenue, cash flow, and profitability, indicating good financial performance.
Dividend
Quest Diagnostics offers a dividend yield of 1.77%, which is reasonable for income-seeking investors. If you invested $1000 you would be paid $29.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DGX
Diagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady testing demand
Routine and chronic‑care testing provides consistent revenue streams, though volumes can shift with public‑health trends and reimbursement changes.
Diagnostic innovation
Growth in molecular and genomic testing and investments in automation may lift margins, but these require capital and carry technological risk.
Market dynamics
Industry consolidation and payer negotiations influence pricing power, so regulatory and competitive shifts can materially affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Chemed Corp.
Provides hospice and palliative care services to patients facing life-limiting illness
Alignment Healthcare, Inc.
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale Senior Living Inc.
A leading owner and operator of senior living communities in the United States.
